Skip to content
    HALO
    Earnings call· Jun 2026(Q2 FY26)

    HALOZYME THERAPEUTICS Q2 FY26 earnings call HALO

    Aug 6, 2026 Source

    Executive summary

    Halozyme Q2 FY26 — Record Royalty Growth and New Deal Momentum

    Halozyme delivered an exceptionally strong second quarter, driven by record ENHANZE royalty revenue growth and significant new collaboration agreements for both ENHANZE and Hypercon. The company is successfully diversifying its revenue streams with multiple new product launches and expanding its platform into new therapeutic modalities like ADCs and nucleic acids, reinforcing its long-term growth trajectory and raising full-year guidance.

    Highlights

    5
    • Total revenue increased 48% year-over-year to $481 million, driven by robust royalty and collaboration revenue.

    • Record total royalty revenue growth of 50% year-over-year to $308 million, supported by new launch products.

    • Signed 4 new collaboration and licensing agreements in Q2, plus a fifth in July, contributing $35.5 million in upfront revenue.

    • Adjusted EBITDA increased 46% to $328.8 million, with an adjusted EBITDA margin of more than 65%.

    • Raised full-year 2026 guidance for total revenue by $110 million at the midpoint, and royalty revenue by $55 million at the midpoint.

    Concerns

    2
    • Merck infringing use of MDAs technology

    • U.S. patent office proceedings (PGRs) and District Court case related to Merck's infringing product

    Guidance & targets

    9
    CategoryTargetConfidence
    Full-year 2026 Total Revenue
    $1.835 billion to $1.91 billion
    high materiality
    High
    Full-year 2026 Royalty Revenue
    $1.22 billion to $1.245 billion
    high materiality
    High
    Full-year 2026 Adjusted EBITDA
    $1.225 billion to $1.28 billion
    high materiality
    High
    Full-year 2026 Non-GAAP Diluted EPS
    $8.65 to $9.00
    high materiality
    High
    ENHANZE Development Programs
    13
    medium materiality
    High
    Hypercon Royalty Revenue
    approximately $1 billion
    high materiality
    High
    OCREVUS IV and subcutaneous sales
    CHF 9 billion
    medium materiality
    High
    OPDIVO Qvantig subcutaneous conversion rate
    30% to 40%
    low materiality
    Medium
    PHESGO global conversion rate
    at least 60%
    low materiality
    High

    Segment performance

    7
    SegmentRevenueYoYQoQMargin
    DARZALEX SC
    Continued robust revenue growth, with strong performance attributed to market growth and share gains across all lines of therapy, including frontline.
    Global sales: >$4 billionGlobal sales growth: ~18% operational growthGlobal sales for SC: virtually allShare gain in frontline setting: nearly 11 percentage points
    $152.2 million27%
    VYVGART Hytrulo
    Strong adoption of the ENHANZE-enabled prefilled syringe (PFS) expanding the prescriber base and bringing new patients into therapy, supporting long-term product growth.
    Total VYVGART brand sales: $1.5 billionTotal VYVGART brand sales growth: 60% YoYU.S. PFS patients new to VYVGART: ~80%
    $72.6 million143%
    OCREVUS SC
    Demonstrating how ENHANZE-enabled delivery expands accessible patient population and reaches new sites of care. Fastest-growing anti-CD20 multiple sclerosis brand in the U.S.
    Patients receiving SC formulation: 44,000Patients at end of Q4 2025: 17,500U.S. OCREVUS ZUNOVO starts from community practices: ~60%
    OPDIVO Qvantig
    Strong launch trajectory with increasing subcutaneous conversion and significant global sales growth.
    Subcutaneous conversion: 15%Global sales: $261 millionGlobal sales growth: >200% YoYProjected annualized revenue: >$1 billion
    RYBREVANT SC
    Rapid uptake contributing to strong brand growth, with a permanent J code awarded to broaden adoption.
    Total RYBREVANT brand growth: 62% YoY
    PHESGO
    Continues to demonstrate value of ENHANZE-enabled subcutaneous delivery within Roche's HER2 franchise, with strong growth and conversion.
    Growth (H1 2026): 18%Global conversion: 54% (in 85 launch countries)
    Other Royalty Revenues (Newer Launches)
    Driven by increasing partner product sales of recently launched ENHANZE products, showing significant early momentum.
    Quarter-on-quarter growth (OPDIVO SC, OCREVUS SC, RYBREVANT SC): 80%
    $54.4 million85%

    Operational metrics

    20
    Total Revenue
    $481 million48% YoY growth
    Q2 FY26

    Driven by robust royalty revenue growth and higher collaboration revenue.

    Royalty Revenue
    $307.7 million50% YoY growth
    Q2 FY26

    Exceeded expectations, reflecting increasing contributions from recently launched ENHANZE products and continued success of established products.

    Collaboration Revenue
    $35.5 million
    Q2 FY26

    Contributed by 4 new collaboration and licensing agreements signed in Q2.

    Adjusted EBITDA
    $329 million46% YoY growth
    Q2 FY26

    Driven by continued strong royalty growth.

    Non-GAAP Diluted EPS
    $2.28vs $1.54 in Q2 2025
    Q2 FY26

    Highlighting the strength of the diversified royalty portfolio and operating leverage.

    R&D Expenses
    $27.7 millionvs $17.5 million in Q2 2025
    Q2 FY26

    Reflecting the addition of Hypercon and Surf Bio and continued investment in advancing technologies.

    SG&A Expenses
    $57 millionvs $41.6 million in Q2 2025
    Q2 FY26
    Net Income
    $229.9 million39% increase
    Q2 FY26

    Compared to $165.2 million in the prior year period.

    GAAP Diluted EPS
    $1.90vs $1.33 in Q2 2025
    Q2 FY26
    Share Repurchases
    $332.8 millionagainst target of $400 million for full year
    Q2 FY26

    Viewed as an attractive use of capital when stock does not fully reflect durability and growth of royalty streams.

    OCREVUS SC Patients
    44,000vs 17,500 at end of Q4 2025
    Q2 FY26

    Number of patients receiving the subcutaneous formulation, demonstrating expansion of accessible patient population.

    OPDIVO Qvantig Annualized Revenue
    >$1 billion
    Annualized

    Projected based on strong launch trajectory and global sales.

    Total IV and SC Opportunity (3 newer products)
    $25 billion
    2028

    Projected based on total sales for OCREVUS, OPDIVO, and RYBREVANT.

    Total Royalty Opportunity (6 products)
    >$55 billion
    Future

    Total opportunity for the diversified set of 6 products contributing royalty revenues.

    VYVGART PFS New Patients
    ~80%
    Q2 FY26

    Percentage of U.S. PFS patients in the quarter reported to be new to VYVGART, demonstrating broadened patient reach.

    VYVGART Addressable Opportunity Expansion
    11,000 patients
    Future

    Expansion of addressable opportunity due to U.S. approval in seronegative GMG.

    ENHANZE Development Programs
    9
    Q2 FY26

    Current number of ENHANZE partner products in development, with 2 new Phase I starts in Q2.

    Hypercon First Launch Timing
    2030-2031
    Future

    Projected first launch timing for Hypercon products.

    Hypercon Launches for $1B Royalty Target
    5 to 7
    mid-2030s

    Assumed number of launches to contribute to the $1 billion Hypercon royalty revenue target.

    ENHANZE New Modality Potential
    at least 100
    Future

    Estimated number of commercial and development products in ADCs and nucleic acids that may benefit from ENHANZE.

    Industry KPIs

    9
    MetricValueDetails
    Launch access metricsPermanent J code awarded
    Pipeline read out calendar9programs
    Regulatory approvals filingsPriority Review granted
    Peak long term sales guidanceCHF 9 billionCHF
    Therapeutic drug market sharenearly 11 percentage points%
    Prescription volume new starts~80%%
    Clinical trial efficacy safety dataPositive Phase III data
    Collaboration milestone royalty revenue$35.5 millionUSD
    Cumulative patients uptake since launch44,000patients

    Product announcements

    3
    ProductTypeDetails
    RYBREVANT FASPRO J codemilestone
    VYVGARTexpansion
    DARZALEX Faspro all subcutaneous regimenexpansion

    Deals & partnerships

    5
    GSKNew ENHANZE agreement

    Included the opportunity to use ENHANZE in a new use area with antibody drug conjugates.

    IncyteNew ENHANZE agreement

    Working with Incyte on a subcutaneous formulation of its first-in-class mutant calorectulin targeted monoclonal antibody.

    undisclosed partnerNew ENHANZE agreement

    To explore the use of ENHANZE within nucleic acid therapeutic, the first collaboration in this emerging area.

    VertexNew Hypercon collaboration agreement

    Established a strategic platform relationship with potential to expand over time.

    OrukaNew Hypercon collaboration agreement

    Established a strategic platform relationship with potential to expand over time.

    Risks & headwinds

    2
    Merck infringing use of MDAs technologyBefore the end of this year (Europe)

    Actively pursuing injunctions in 8 countries outside the U.S.

    Mitigation: Seeking injunctions to stop Merck's launch, manufacturing, distribution, and supply of infringing products; preliminary injunction already granted in Germany.

    U.S. patent office proceedings (PGRs) and District Court case related to Merck's infringing productThis fall (PTAB decision), later this year (clarity on District Court timing)

    Appealing initial PTAB written decisions; awaiting PTAB's decision on remaining 10 PGRs.

    Mitigation: Appealing PTAB decisions; strong conviction that Merck's product is infringing; confident in prevailing.

    What to watch in Q3 FY26

    5

    Merck Litigation Decisions (Europe)

    Before the end of this year
    CurrentPreliminary injunction in Germany in December; actively pursuing injunctions in 8 countries.
    TargetImportant decisions broadly impacting Merck launches/sales in Europe.

    Why it matters

    These decisions could significantly impact Merck's ability to commercialize infringing products outside the U.S., affecting Halozyme's royalty streams and competitive landscape.

    And we do expect important decisions broadly impacting Merck launches of sales in [indiscernible] in Europe before the end of this year.

    Q&A highlights

    7

    What is driving the implied sequential step-up in royalty revenue from Q2's $308 million to $336-$348 million per quarter in the back half, as per the raised full-year guidance? Is it primarily newer launches or established products?

    Management expects royalty revenue to grow sequentially through H2, driven largely by newer product launches like RYBREVANT subcu, which are starting to pick up. While Q1 to Q2 had significant step-ups, the ramp-up will continue.

    Yes. Thanks for the question. And as you noted, royalties were an important component of the beat in the first half. And I would say that we do expect royalty revenue to grow sequentially through the second half. Probably won't have quite the same amount of royalty step-ups that were part of the Q1 to Q2 growth. But we do expect that to continue to ramp up in the second half. And a lot of it is driven by some of the new product launches that you've seen, so things like RYBREVANT subcu, which has started to pick up a little bit in some of the other new products.

    asked by Natasha on for Sean Laaman, Morgan Stanley · answered by Darren Snellgrove

    3 min read7 chapters

    Detailed Narrative

    01

    ENHANZE Platform Performance and Diversification

    Halozyme's ENHANZE platform continues to demonstrate repeatability, scalability, and durability, driving record royalty revenue growth. The company has successfully diversified its royalty streams from a focus on DARZALEX SC to now include PHESGO, VYVGART Hytrulo, and newer launches like OPDIVO SC, OCREVUS SC, and RYBREVANT SC, which collectively grew 80% quarter-on-quarter. This broadened portfolio resulted in a 50% year-over-year increase in total royalty revenue to $308 million, supporting long-term financial guidance.

    02

    Hypercon as a Second Compounding Engine

    Hypercon is emerging as a second platform engine, designed for lower volume subcutaneous administration and highly concentrated formulations. The company is advancing preparations for the first Hypercon clinical starts in H1 2027, with projected first product launches in 2030-2031. Halozyme expects Hypercon to achieve approximately $1 billion in royalty revenue by the mid-2030s, with 5 to 7 launches contributing to this target, potentially from both existing and future agreements.

    03

    Record New Collaboration Agreements

    Halozyme signed 4 new collaboration and licensing agreements in Q2 and a fifth in July, marking its most successful year for new deals. These include three new ENHANZE agreements (with GSK, Incyte, and an undisclosed partner) and two new Hypercon agreements (with Vertex and Oruka). Notably, ENHANZE expanded into new modality areas: Antibody Drug Conjugates (ADCs) and nucleic acids, representing new growth segments with an estimated 100 commercial and development products that could benefit. These new CLAs contributed $35.5 million in upfront collaboration revenue.

    04

    Pipeline Expansion and Future Royalty Streams

    The company is actively expanding its pipeline of future royalty streams, with 2 new ENHANZE targets initiating Phase I testing in Q2, bringing the total to 9 development programs. Halozyme aims to have 13 ENHANZE development programs by year-end 2026, with potential approvals beginning in the 2029+ timeframe. This growing portfolio of future launches is expected to extend revenue opportunities well into the next decade, layering on top of currently approved products.

    05

    Capital Allocation and M&A Strategy

    Halozyme maintains a disciplined capital allocation strategy focused on funding high-return organic opportunities, maintaining a strong balance sheet, and returning excess capital through share repurchases. The company bought back $332.8 million worth of shares in Q2, targeting $400 million for the full year. While M&A is considered an important part of the strategy for adding differentiated technologies, the focus for 2026 remains on organic growth, with M&A being unlikely this year due to the strong internal portfolio and growing cash flows.

    06

    Merck Litigation Update

    Halozyme is actively pursuing injunctions in 8 countries outside the U.S. against Merck for infringing use of its technology, with important decisions expected in Europe before year-end. In the U.S., the company is appealing initial PTAB decisions on PGRs and awaiting clarity on the remaining 10 PTAB decisions this fall, which will inform the timing of📎 the U.S. District Court case. Halozyme expresses unwavering confidence in prevailing, citing the infringing nature of Merck's product.

    07

    Competitive Landscape and Moat

    Management views Alteogen as not directly competing, as companies signing deals with Alteogen often target areas where Halozyme has exclusive licenses. Halozyme emphasizes its competitive moat, built on a track record of success, a large safety database (1.3 million patients, 15 years), reliability of supply, and expertise in supporting rapid clinical advancement and innovative trial designs, which continues to attract new partners.

    AI-generated summary of the company’s earnings call. Not investment advice.